This issue of the Journal contains two articles refi ning and advancing the breast cancer risk assessment model known as the Gail Model ( 1 ). This model has been shown to be well calibrated with respect to predicting the number of cancers likely to develop within cohorts of white American women with specifi c risk factors ( 2 -4 ) . As needs of the chemoprevention trials (for determining eligibility) and clinicians (in counseling patients) have grown, the Gail Model has been modifi ed to account for history of atypia and race or ethnicity, but until now it has included only nonmodifi able risk factors (i.e., age, reproductive history, and biopsy history). It is readily available to practitioners as a user-friendly program ( http://bcra.nci.nih.gov/brc/start.htm ).
speculative in nature ( 7 -9 ) . Current efforts to incorporate breast density into the Gail Model offer tripartite benefi ts: 1) breast density appears to represent a truly individualized risk factor that increases the discriminatory accuracy of prediction models to more than 0. 6 ( 5 , 6 ) , 2) breast density may be more uniformly predictive of breast cancer risk in multiethnic populations ( 10 , 11 ) , and 3) breast density may also represent a modifi able risk factor that can monitor responsiveness to lifestyle and/or medical prevention strategies. Interestingly, in both studies, breast density was more predictive of risk than family history of breast cancer, despite the fact that two different measures of breast density were used.
In its present form, the calibration strength of the Gail Model substantiates the fulfi llment of its goal to identify cohorts of highrisk patients who are appropriate participants for chemoprevention trials. However, the discriminatory accuracy of the Gail Model at 0.5 -0.6 suggests that it is only slightly better than chance in generating a higher risk estimate for a woman with versus without a diagnosis of breast cancer ( 12 ) . Furthermore, the medical community has defaulted to generalizing the Gail Model, the best available risk prediction model for white women, to women of all racial or ethnic backgrounds. Although the model is quite valuable for defi ning chemoprevention trial eligibilty, it is somewhat less able to assist in counseling the individual patient who visits a clinician's offi ce and desires advice regarding whether she should face the morbidity of a chemoprevention medication. Risk assessment that uses an anatomic-based or tissue-based biomarker would be a more rational tool, but the ability to retrieve evaluable tissue from the general population is an obvious obstacle. Assessment of an individual woman's breast density may be the nextbest option, as shown by Chen et al. and by Barlow et al.
Despite the potential for breast density to improve the precision of the Gail Model, it is incumbent upon the medical community to consider the feasibility of its widespread use by looking at contemporary mammography-reporting practices. Mammography facilities in the United States are accredited through the Food and Drug Administration through their adherence to the Mammography Quality Standards Act (MQSA) of 1994. MQSA inspections monitor mammogram reports to ensure presentation of clear, fi nal impressions as " negative, " " benign, " " probably benign, " " suspicious, " or " highly suggestive of malignancy. " MQSA descriptors correlate with the numbered categories as defi ned by the American College of Radiology (ACR) in the Breast Imaging Reporting and Data System (BI-RADS). The ACR has also developed the following set of fi broglandular density descriptors that may be used within the text of a mammogram report: " almost entirely fat " (<25% density), " scattered fi broglandular densities " (25% -50%), " heterogeneously dense " (51% -75%), and " extremely dense " (>75%). The prospective clinical trial of digital versus fi lm-screen mammograms ( 13 ) found that breast density is a useful indicator of women that benefi t from digital mammography, and this result has motivated many mammographers to routinely incorporate the BI-RADS density descriptors into their reports. However, it must be noted that mammography facilities currently have no MQSA mandate to include breast density into their reporting mechanism. Furthermore, one meta-analysis of breast density and breast cancer risk ( 10 ) found that the correlation is strongest when density is reported as percentage density as opposed to qualitative categories, such as the BI-RADS descriptors. Barlow et al. used the ACR descriptors to stratify breast density; however, Chen et al. used a fi ve-category stratifi cation of percentage density measurements. Standardization of breast density reporting must be achieved before breast density can be adapted into a clinically useful risk assessment model.
Inclusion of breast density, and perhaps other modifi able risk factors, is indeed exciting in the ongoing evolution of breast cancer prediction tools and our quest for accurate, individualized estimates. However, we must continue to exercise caution with these adjustments; a perfectly predictive model will be of minimal value if its component factors are unavailable, misunderstood, or inappropriately assigned.
